This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pasello, M. Articles by Serra, M. Search for Related Content PubMed PubMed Citation Articles by Pasello, M. Articles by Serra, M.

Overcoming Glutathione S-Transferase P1–Related Cisplatin Resistance in Osteosarcoma

¹ Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy and ² Dipartimento di Scienze e Tecnologie Chimiche, Università Tor Vergata, Rome, Italy

Requests for reprints: Massimo Serra, Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy. Phone: 39-051-636-6762; Fax: 39-051-636-6761; E-mail: massimo.serra{at}ior.it.

Key Words: sarcoma/soft-tissue malignancies • novel antitumor agents • glutathione metabolism • new targets • nontransporters-related multidrug resistance

Cisplatin (cis-diamminedichloroplatinum, CDDP) is one of the most used drugs for osteosarcoma chemotherapy. By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). On the basis of these findings, we evaluated the clinical effect of GSTP1 in a series of 34 high-grade osteosarcoma patients and we found that the increased expression of GSTP1 gene was associated with a significantly higher relapse rate and a worse clinical outcome. These indications prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a promising new anticancer agent that is a highly efficient inhibitor of GSTP1. NBDHEX was tested on a panel of 10 human osteosarcoma cell lines and 20 variants of the U-2OS or Saos-2 cell lines that were resistant to CDDP, doxorubicin, or methotrexate. NBDHEX proved to be very active on the vast majority of these cell lines, including those with higher GSTP1 levels and enzymatic activity. Drug combination studies showed that NBDHEX can be used in association with CDDP and provided useful information about the best modality of their combined administration. In conclusion, our findings show that GSTP1 has a relevant effect for both CDDP resistance and clinical outcome of high-grade osteosarcoma and that targeting GSTP1 with NBDHEX may be considered a promising new therapeutic possibility for osteosarcoma patients who fail to respond to conventional chemotherapy. [Cancer Res 2008;68(16):6661–8]

This article has been cited by other articles:

				L. Federici, C. Lo Sterzo, S. Pezzola, A. Di Matteo, F. Scaloni, G. Federici, and A. M. Caccuri Structural Basis for the Binding of the Anticancer Compound 6-(7-Nitro-2,1,3-Benzoxadiazol-4-Ylthio)Hexanol to Human Glutathione S-Transferases Cancer Res., October 15, 2009; 69(20): 8025 - 8034. [Abstract] [Full Text] [PDF]

				Z. Duan, E. Choy, D. Harmon, C. Yang, K. Ryu, J. Schwab, H. Mankin, and F. J. Hornicek Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Mol. Cancer Ther., August 1, 2009; 8(8): 2122 - 2130. [Abstract] [Full Text] [PDF]